CoChat

Turning the tide on Alzheimer’s disease: modulation of γ-secretase

Open access
Luo, Joanna E., Li, Yue-Ming · 2022 · Cell & Bioscience

The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.

Abstract

Alzheimer’s disease (AD) is the most common type of neurodegenerative disorder. Amyloid-beta (Aβ) plaques are integral to the “amyloid hypothesis,” which states that the accumulation of Aβ peptides triggers a cascade of pathological events leading to neurodegeneration and ultimately AD. While the FDA approved aducanumab, the first Aβ-targeted therapy, multiple safe and effective treatments will be needed to target the complex pathologies of AD. γ-Secretase is an intramembrane aspartyl protease that is critical for the generation of Aβ peptides. Activity and specificity of γ-secretase are regulated by both obligatory subunits and modulatory proteins. Due to its complex structure and function and early clinical failures with pan inhibitors, γ-secretase has been a challenging drug target for AD. γ-secretase modulators, however, have dramatically shifted the approach to targeting γ-secretase. Here we review γ-secretase and small molecule modulators, from the initial characterization of a subset of NSAIDs to the most recent clinical candidates. We also discuss the chemical biology of γ-secretase, in which small molecule probes enabled structural and functional insights into γ-secretase before the emergence of high-resolution structural studies. Finally, we discuss the recent crystal structures of γ-secretase, which have provided valuable perspectives on substrate recognition and molecular mechanisms of small molecules. We conclude that modulation of γ-secretase will be part of a new wave of AD therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13578-021-00738-7

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 γ-secretase and its obligatory subunits. Catalytic aspartyl residues are indicated by stars. Adapted from “Gamma secretase” by BioRender.com (2021)
Fig. 1 γ-secretase and its obligatory subunits. Catalytic aspartyl residues are indicated by stars. Adapted from “Gamma secretase” by BioRender.com (2021)CC BY · PubMed Central
Fig. 2 APP processing by γ-secretase. β-secretase cleaves APP to generate βCTF (C99) and release soluble APP (sAPPβ). Afterwards γ-secretase cleaves βCTF between Aβ49 or Aβ48 (ε-cleavage), resulting in two product lines. Further processing (ζ- and γ- cleavages) generates Aβ peptides released into the extracellular space. Created with BioRender.com
Fig. 2 APP processing by γ-secretase. β-secretase cleaves APP to generate βCTF (C99) and release soluble APP (sAPPβ). Afterwards γ-secretase cleaves βCTF between Aβ49 or Aβ48 (ε-cleavage), resulting in two product lines. Further processing (ζ- and γ- cleavages) generates Aβ peptides released into the extracellular space. Created with BioRender.comCC BY · PubMed Central
Fig. 3 Structures of γ-secretase inhibitors in AD clinical trials
Fig. 3 Structures of γ-secretase inhibitors in AD clinical trialsCC BY · PubMed Central
Fig. 4 Structures of representative first generation γ-secretase modulators
Fig. 4 Structures of representative first generation γ-secretase modulatorsCC BY · PubMed Central
Fig. 5 Structures of representative second generation γ-secretase modulators (A) Carboxylic acid NSAID-derived GSMs and (B) Heterocyclic non-NSAID derived GSMs
Fig. 5 Structures of representative second generation γ-secretase modulators (A) Carboxylic acid NSAID-derived GSMs and (B) Heterocyclic non-NSAID derived GSMsCC BY · PubMed Central
Fig. 6 Structures of γ-secretase modulators in clinical trials
Fig. 6 Structures of γ-secretase modulators in clinical trialsCC BY · PubMed Central
Fig. 7 Multiple binding sites on PS1 established by photoaffinity labeling studies. L458 binds to the active site. GSMs such as GSM-1 and E2012 bind to allosteric sites and alter the conformation of the active site
Fig. 7 Multiple binding sites on PS1 established by photoaffinity labeling studies. L458 binds to the active site. GSMs such as GSM-1 and E2012 bind to allosteric sites and alter the conformation of the active siteCC BY · PubMed Central
Fig. 8 Visualization of γ-secretase bound to Semagacestat, Avagacestat, and L-685,458. PS1 is represented in orange. Protein Data Bank entries 6LR4, 6LQG, and 7C9I, respectively
Fig. 8 Visualization of γ-secretase bound to Semagacestat, Avagacestat, and L-685,458. PS1 is represented in orange. Protein Data Bank entries 6LR4, 6LQG, and 7C9I, respectivelyCC BY · PubMed Central
Fig. 9 A Visualization of γ-secretase bound to E2012. PS1 is represented in orange and NCT is represented in green. Hydrogen bond between methylimidazole on E2012 and Tyr106 on PS1 is indicated by the dotted blue line. B Visualization of allosteric site and active site on γ-secretase. γ-secretase subunits represented are PS1 (green), Nicastrin (blue), PEN-2 (pink), and APH-1 (brown). Protein Data Bank entry 7D8X
Fig. 9 A Visualization of γ-secretase bound to E2012. PS1 is represented in orange and NCT is represented in green. Hydrogen bond between methylimidazole on E2012 and Tyr106 on PS1 is indicated by the dotted blue line. B Visualization of allosteric site and active site on γ-secretase. γ-secretase subunits represented are PS1 (green), Nicastrin (blue), PEN-2 (pink), and APH-1 (brown). Protein Data Bank entry 7D8XCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 89 references

Research works printed but not linked: 2

  1. Nagy CSE, Ishibashi A, Nakatani Y, Rege B, Logovinsky V. E2012, a novel gamma-secretase modulator, decreases plasma amyloid-beta levels in humans. Alzheimers Dement. 2010;6:S574.
  2. Hashimoto TI, Hagiwara H, Murata Y, Takenaka O, Miyagawa T. A novel gamma-secretase modulator—pharmacology. Alzheimers Dement. 2010;6:S242.

Cited by

See all 59

Metadata

Authors
Luo, J. E., & Li, Y.-M.
Affiliations
Memorial Sloan Kettering Cancer Center (US)
Corresponding author
  • Luo, Joanna E.
  • Li, Yue-Ming
Venue
Cell & Bioscience
Published
2022-01-04
Volume
12
Issue
1
Pages
2-2
ISSN
2045-3701 (ISSN-L)
OpenAlex
W4206369042
Cited by
59
References
89
Citations by year
2026: 9 · 2025: 10 · 2024: 18 · 2023: 12 · 2022: 10
FWCI
1.72
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell & Bioscience (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health (R01NS096275, RF1AG057593, R01AG061350)
  • JPB Foundation
  • Metropolitan Life Insurance Company
  • Cure Alzheimer's Fund
  • Edward N. and Della L. Thome Memorial Foundation
  • Coins for Alzheimer's Research Trust
  • National Institute on Aging (F31AG064813)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, gamma-secretase, γ-secretase modulators, amyloid-beta, amyloid hypothesis, aducanumab, nonsteroidal anti-inflammatory drugs, chemical probes, chemical biology, crystal structure, substrate recognition, neurodegeneration, therapeutic target

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Turning the tide on Alzheimer’s disease: modulation of γ-secretase. https://app.cochat.ai/papers/10.1186/s13578-021-00738-7
The paper
Luo, J. E., & Li, Y.-M. (2022). Turning the tide on Alzheimer’s disease: modulation of γ-secretase. Cell & Bioscience. https://doi.org/10.1186/s13578-021-00738-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.